Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer

BOIRON : 2022 half-year sales
information fournie par Actusnews 22/07/2022 à 15:05

(Unaudited data)

CUMULATIVE SALES AS OF THE END OF JUNE 2022

In thousands of euros 2022 2021 Variation at current
exchange rates
Variation at constant exchange rates
France 131,338 104,930 +25.2% +25.2%
Europe (excluding France) 60,704 42,234 +43.7% +42.7%
North America 52,227 35,380 +47.6% +34.3%
Other countries 12,494 7,388 +69.1% +56.8%
Group total 256,762 189,931 +35.2% +32.0%
In thousands of euros 2022 2021 Variation at current
exchange rates
Variation at constant exchange rates
Non-proprietary homeopathic medicines 88,876 93,994 -5.4% -6.8%
Homeopathic specialties 121,916 80,113 +52.2% +46.5%
Other health products* 45,970 15,825 +190.5% +189.0%
Group total 256,762 189,931 +35.2% +32.0%

SALES BY QUARTER (VARIATION AT CURRENT EXCHANGE RATES)

In thousands of euros 1 st quarter 2 nd quarter
2022 2021 Var. 2022 2021 Var.
France 77,055 51,518 +49.6% 54,283 53,412 +1.6%
Europe (excluding France) 34,476 20,039 +72.0% 26,228 22,194 +18.2%
North America 28,944 17,657 +63.9% 23,282 17,723 +31.4%
Other countries 5,305 1,958 +171.0% 7,189 5,430 +32.4%
Group total 145,780 91,172 +59.9% 110,982 98,759 +12.4%
In thousands of euros 1 st quarter 2 nd quarter
2022 2021 Var. 2022 2021 Var.
Non-proprietary homeopathic medicines 45,516 46,352 -1.8% 43,360 47,642 -9.0%
Homeopathic specialties 67,100 39,430 +70.2% 54,816 40,683 +34.7%
Other health products* 33,164 5,390 +515.3% 12,806 10,434 +22.7%
Group total 145,780 91,172 +59.9% 110,982 98,759 +12.4%

* “Other health products” include non-homeopathic products (medical devices, dietary supplements, cosmetics, phytotherapy), which were presented under “specialties” until 2021.

Change in revenue

In the second quarter:

Revenues continue to grow, in particular thanks to homeopathic medicines and other health products. Sales of homeopathic specialties rose 34.7%, thanks to the continued increase in the winter range, essentially in France, the United States, Canada and Italy.

The decline in non-proprietary homeopathic medicines is mainly attributable to France.

In the first half:

Total sales increased 35.2%. This increase breaks down more or less evenly between existing homeopathic specialties and new products.

Regarding new products launched in 2020 (homeopathic medicines and other healthcare products), sales amounted to approximately 47 million euros in the first half, compared to 15 million euros in the first half of 2021.

This strong growth in all regions is the result of the Group's proven resilience, founded on the strength of its brands, innovation strategy, commitment of its teams and flexibility of its industrial equipment.

Outlook

Amid rising inflation and supply chain pressures, we are doing everything we can to ensure our medicines and entire product range remain available.

We are also keeping a close eye on how the global health crisis evolves, and continue to take appropriate measures where necessary.

In light of the significant increase in business and the impact of the reorganization carried out in France, the Group expects to achieve a sharp increase in operating income in the first half.

In total over the year, we therefore expect to see an increase in revenue and profitability compared to 2021.

We continue to put all our energy and determination into the promotion of homeopathy in France and around the world.

Laboratoires BOIRON


Our next update:
September 7, 2022: at market close, publication of 2022 half-year results.
Person responsible for financial information: Valérie Lorentz-Poinsot.
Contact for financial information: Fabrice Rey.
Investor relations: +33 (0) 4.37.41.84.01 - e-mail: boironfinances@boiron.fr

ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com



Cette publication dispose du service " 🔒 Actusnews SECURITY MASTER ".
- SECURITY MASTER Key : lW5qkZVtkpvGnWltZ55naWSYZmyWxZSXaWrKk2NxZZyYmXKVx2pql5mWZnBmm2tp
- Pour contrôler cette clé : https://www.security-master-key.com .



Information réglementée :
Informations privilégiées :
- Communiqué sur comptes, résultats


Communiqué intégral et original au format PDF : https://www.actusnews.com/news/75663-boi-210722-ca-t2-gb.pdf

© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Valeurs associées

22,250 EUR Euronext Paris -0,45%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

  • Wall Street finit en hausse, S&P-500 et Nasdaq proches de leurs records
    information fournie par Reuters 27.06.2025 00:06 

    par Stephen Culp La Bourse de New York a fini en hausse jeudi, alors que le fragile cessez-le-feu entre Israël et l'Iran continuait de tenir et que des données économiques ont alimenté la perspective de voir la Réserve fédérale américaine (Fed) assouplir sa politique ... Lire la suite

  • Deux opérateurs à la Bourse de New York le 13 juin 2025 ( AFP / ANGELA WEISS )
    information fournie par AFP 26.06.2025 22:30 

    La Bourse de New York a terminé en hausse jeudi, le S&P 500 se rapprochant de son sommet historique alors que les investisseurs digèrent de nouvelles données sur l'économie américaine et la politique commerciale de Donald Trump. Le Dow Jones a gagné 0,94%,

  • La salle de contrôle d'Euronext, société qui gère la Bourse de Paris ( AFP / ERIC PIERMONT )
    information fournie par AFP 26.06.2025 18:51 

    La Bourse de Paris a terminé sans changement (-0,01%) jeudi, à l'issue d'une séance sans événement majeur pour donner une impulsion à la place financière française, dans un marché toutefois soulagé par l'accalmie des tensions géopolitiques. L'indice vedette CAC ... Lire la suite

  • Le reflet d'un tableau digital à la bourse Euronext dans le quartier d'affaires de La Défense à Paris
    information fournie par Reuters 26.06.2025 18:22 

    par Claude Chendjou Les Bourses européennes ont terminé sur de faibles variations jeudi en l'absence de catalyseurs majeurs alors que l'impact positif de la trêve entre l'Iran et Israël commence à s'atténuer. À Paris, le CAC 40 a fini sur une perte de 0,01% à 7.557,31 ... Lire la suite

Mes listes

Cette liste ne contient aucune valeur.